Table 2. Patient characteristics of the afatinib treated group according to T790M mutation.
| T790M + (N = 22) | T790M − (N = 7) | P-value | |
|---|---|---|---|
| Median age (years; range) | 60 (32–81) | 56 (44–67) | 0.45 |
| Sex | 0.55 | ||
| Male | 4 | 2 | |
| Female | 18 | 5 | |
| ECOG Performance status | 0.12 | ||
| 0 | 12 | 1 | |
| 1 | 9 | 6 | |
| 2 | 1 | 0 | |
| Ethnic origin | 0.49 | ||
| White | 19 | 7 | |
| Asian | 2 | 0 | |
| Afro-American | 1 | 0 | |
| Smoking history (at start afatinib treatment) | 0.33 | ||
| Never smoker | 10 | 5 | |
| Ex-smoker | 10 | 1 | |
| Current smoker | 0 | 0 | |
| Unknown | 2 | 1 | |
| Number of lines of previous chemotherapy | 0.29 | ||
| 0 | 11 | 1 | |
| 1 | 3 | 4 | |
| 2 | 6 | 2 | |
| >2 | 2 | 0 | |
| EGFR TKI before afatinib | <0.001 | ||
| erlotinib | 18 | 1 | |
| gefitinib | 2 | 6 | |
| both subsequently | 4 | 1 |